Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0UW6S
|
|||
Drug Name |
PMID29053063-Compound-4
|
|||
Drug Type |
Small molecular drug
|
|||
Company |
INSERM INST NAT DE LA SANT ET DE LA RECH M DICALE [FRUNIVERSIT PARIS DIDEROT PARIS 7 [FRCENTRE NAT RECH SCIENT [FR]
|
|||
Structure |
Download2D MOL |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Monoglyceride lipase (MAGL) | Target Info | Inhibitor | [1] |
Target's Patent Info | Monoglyceride lipase (MAGL) | Target's Patent Info | [1] | |
BioCyc | Triacylglycerol degradation | |||
KEGG Pathway | Glycerolipid metabolism | |||
Metabolic pathways | ||||
Retrograde endocannabinoid signaling | ||||
NetPath Pathway | EGFR1 Signaling Pathway | |||
Reactome | Acyl chain remodeling of DAG and TAG | |||
Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | ||||
WikiPathways | Lipid digestion, mobilization, and transport | |||
Glycerophospholipid biosynthesis | ||||
GPCR downstream signaling | ||||
Effects of PIP2 hydrolysis |
References | Top | |||
---|---|---|---|---|
REF 1 | A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.